PRCL Research Overview
- Founded
-
2014
- Status
-
Out of Business
- Latest Deal Type
-
Out of Business
PRCL Research General Information
Description
Developer of oral drug compounds intended to treat psoriasis. The company's compounds specifically inhibit T-cell activity and are created for a special purpose of targeting the exact cause of the disease, enabling physicians to treat their patients in an enhanced way.
Contact Information
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Primary Office
- 1255 University
- Suite 1610
- Montreal, Quebec H3B 3X3
- Canada
PRCL Research Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Out of Business | 01-Jun-2019 | Completed | Out of Business | |||
| 1. Early Stage VC | 12-May-2014 | Completed | Startup |
PRCL Research Patents
PRCL Research Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2012250788-A1 | Compounds for inflammation and immune-related uses | Active | 03-May-2011 | 0000000000 | |
| AU-2012250788-B2 | Compounds for inflammation and immune-related uses | Inactive | 03-May-2011 | 0000000000 | 0 |
| CA-2834928-C | Compounds for inflammation and immune-related uses | Inactive | 03-May-2011 | 0000000000 | |
| CA-2834928-A1 | Compounds for inflammation and immune-related uses | Active | 03-May-2011 | 0000000000 | |
| EP-2704701-B1 | Compounds for inflammation and immune-related uses | Active | 03-May-2011 | C07D417/14 |